Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis
- PMID: 29421431
- DOI: 10.1016/j.neuroscience.2018.01.042
Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis
Abstract
The neuromuscular junction (NMJ) is a peripheral synapse between motor neurons and skeletal muscle fibers that controls muscle contraction. The NMJ is the target of various disorders including myasthenia gravis (MG), an autoimmune disease in which auto-antibodies (auto-Abs) attack the synapse, and thus cause muscle weakness in patients. There are multiple auto-Abs in the MG patient sera, but not all the Abs are proven to be pathogenic, which increases the difficulties in clinical diagnoses and treatments. To establish the causative roles of auto-Abs in MG pathogenesis, the experimental autoimmune MG (EAMG) induced by the active immunization of auto-antigens (auto-Ags) or the passive transfer of auto-Abs is required. These models simulate many features of the human disease. To date, there are three kinds of EAMG models reported, of which AChR-EAMG and MuSK-EAMG are well characterized, while the recent LRP4-EAMG is much less studied. Here, we report a current summary of LRP4-EAMG and its pathogenic mechanisms. The features of LRP4-EAMG are more similar to those of AChR-EAMG, indicating a similar clinical treatment for LRP4- and AChR-positive MG patients, compared to MuSK-positive MG patients.
Keywords: LRP4; experimental autoimmune myasthenia gravis; myasthenia gravis; neuromuscular junction; synapse.
Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.Immunol Invest. 2017 Jul;46(5):490-499. doi: 10.1080/08820139.2017.1299754. Epub 2017 Apr 4. Immunol Invest. 2017. PMID: 28375749
-
Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Arch Immunol Ther Exp (Warsz). 2012 Feb;60(1):19-30. doi: 10.1007/s00005-011-0158-6. Epub 2011 Dec 8. Arch Immunol Ther Exp (Warsz). 2012. PMID: 22159475 Review.
-
IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.J Neuroimmunol. 2015 Apr 15;281:68-72. doi: 10.1016/j.jneuroim.2015.03.004. Epub 2015 Mar 6. J Neuroimmunol. 2015. PMID: 25867470 Free PMC article.
-
Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.J Autoimmun. 2014 Nov;54:51-9. doi: 10.1016/j.jaut.2014.06.003. Epub 2014 Jun 24. J Autoimmun. 2014. PMID: 24970384 Review.
-
Development of a refined experimental mouse model of myasthenia gravis with anti-acetylcholine receptor antibodies.Front Immunol. 2025 Mar 31;16:1521382. doi: 10.3389/fimmu.2025.1521382. eCollection 2025. Front Immunol. 2025. PMID: 40230859 Free PMC article.
Cited by
-
Recent advances in understanding and managing myasthenia gravis.F1000Res. 2018 Oct 31;7:F1000 Faculty Rev-1727. doi: 10.12688/f1000research.15973.1. eCollection 2018. F1000Res. 2018. PMID: 30443340 Free PMC article. Review.
-
Human neuromuscular junction three-dimensional organoid models and the insight in motor disorders.J Mol Cell Biol. 2022 Jan 21;13(11):767-773. doi: 10.1093/jmcb/mjab046. J Mol Cell Biol. 2022. PMID: 34270721 Free PMC article.
-
Animal Models of the Neuromuscular Junction, Vitally Informative for Understanding Function and the Molecular Mechanisms of Congenital Myasthenic Syndromes.Int J Mol Sci. 2018 Apr 29;19(5):1326. doi: 10.3390/ijms19051326. Int J Mol Sci. 2018. PMID: 29710836 Free PMC article. Review.
-
Neuromuscular Development and Disease: Learning From in vitro and in vivo Models.Front Cell Dev Biol. 2021 Oct 27;9:764732. doi: 10.3389/fcell.2021.764732. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34778273 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous